Ropes & Gray along with Wilson Sonsini advised on Gilead’s $7.8 billion acquisition of Arcellx.
Gilead Sciences, Inc. has entered into a definitive agreement to acquire Arcellx, a biotechnology company developing innovative immunotherapies for cancer and other incurable diseases, for $115 per share in cash at closing and one contingent value right of $5 per share, representing an implied equity value of $7.8 billion.
Gilead, headquartered in Foster City, California, operates in over 35 countries and has delivered breakthroughs in medicine for more than three decades.
Ropes & Gray acted as legal counsel to Gilead Sciences on all aspects of the acquisition.
The team was led by Mergers & Acquisitions Partner Emily Oldshue and Counsel Nick Roper, and included Mergers & Acquisitions Partner Paul Kinsella, Executive Compensation & Employee Benefits Partner Renata Ferrari, IP Transactions Partner Megan Baca, Tax Partners Benjamin Rogers and David Saltzman, Health Care Partner Christine Moundas, Life Sciences Regulatory & Compliance Partner Josh Oyster, and Real Estate Partner David Kaye.
Wilson Sonsini Goodrich & Rosati acted as legal counsel to Arcellx.
The deal reporting on this platform is based on the information received from law firms, and therefore, some details may be missing/incomplete. If your firm has not been credited for this deal, write to us at chanchal.makhija@thegreymatter.co.in mentioning your firm’s name, lawyers involved (including designation) and client represented.
